RELATIVE BIOAVAILABILITY OF CEPHALEXIN DIFFERENT BRANDS OF CAPSULES

In a cross over study eight normal human volunteers were employed. The bioavailability of different commercial brands of cephalexin capsules were examined. The relative bioavailability offour brand (J.I,J.II,L.I,L.II) manufactured by two different domestic cornpai.ies were compaired with one brand (Keflex) which was manufacrurea by Lilly pharmaceutical company, England. The plasma and urine cephalexin concentration were determined by microbiological assay (disk diffusion) using Sarcina LuteaATCC 9341 as test organism. Plasma and urine data were used to evaluate various pharmacokinetic parameters cephalexin including K,tl/':b C1/F, Vd/F, T max, CmaxAUC and F (relative).
Results obtained from urinary data were supported the plasma data. The analysis of variance, to compare relative bioavailability and other pharmacokinetic parameters between tested samples were performed. These information indicates that there are no significant differences between the five different tested brands and they are bioequivalent. Therefore it can be suggested that brands (J.I,J.II,L.I,L.II) which formulated by domestic manufactures are bioequivalent and comparable to each other and to the one formulated by Lilly pharmaceutical company.